| 1. |
- Johansson, Tord, et al.
(författare)
-
Results from PS185.
- 1999
-
Ingår i: NUCLEAR PHYSICS A. - : ELSEVIER SCIENCE BV. ; , s. 173C-178C
-
Konferensbidrag (refereegranskat)abstract
- The PS185 experiment at LEAR/CERN has studied strangeness production in antiproton-proton collisions. Exclusive final states of antihyperon-hyperon pairs have been measured in order to investigate strange-quark production dynamics. A comprehensive data se
|
|
| 2. |
- Barnes, PD, et al.
(författare)
-
Antihyperon-hyperon production in the threshold region at LEAR
- 1996
-
Ingår i: PHYSICS OF ATOMIC NUCLEI. - : AMER INST PHYSICS. ; , s. 1460-1466
-
Konferensbidrag (refereegranskat)abstract
- The experiment PSI185 studies the antihyperon-hyperon production in antiproton-proton annihilation at LEAR/CERN up to 2 GeV/c. This is achieved by investigation of the channels (p) over bar p --> <(Lambda)over bar>Lambda, <(Lambda)over bar>Sigma(0) + c.c.
|
|
| 3. |
- Barnes, PD, et al.
(författare)
-
Observables in high-statistics measurements of the reaction (p)over-bar-p->(Lambda)over-bar-Lambda
- 1996
-
Ingår i: PHYSICAL REVIEW C-NUCLEAR PHYSICS. - : AMER INST PHYSICS. - 0556-2813. ; 54:4, s. 1877-1886
-
Tidskriftsartikel (refereegranskat)abstract
- Associated strangeness production has been studied in the <(p)over bar p> --> <(Lambda)over bar Lambda> --> <(p)over bar pi(+)> p pi(-) reaction at the CERN antiproton facility LEAR using the experimental setup of PS185. Results from two high-statistics m
|
|
| 4. |
|
|
| 5. |
- WEINANDER, R, et al.
(författare)
-
Heterologous expression of rat liver microsomal glutathione transferase in simian COS cells and Escherichia coli
- 1995
-
Ingår i: The Biochemical journal. - : Portland Press Ltd.. - 0264-6021 .- 1470-8728. ; 311311 ( Pt 3), s. 861-866
-
Tidskriftsartikel (refereegranskat)abstract
- The cDNA coding for rat liver microsomal glutathione transferase was subcloned into the mammalian expression vector pCMV-5 and the construct was transfected into, and transiently expressed in, simian COS cells. This resulted in high expression (0.7% of the microsomal protein). The activity towards 1-chloro-2,4-dinitrobenzene in microsomes was 15-30 nmol/min per mg, which increased upon N-ethylmaleimide treatment to 60-200 nmol/min per mg. Control and antisense-vector-treated cells displayed very low activity (3-6 nmol/min per mg). A DNA fragment coding for rat microsomal glutathione transferase was generated by PCR, cloned into the bacterial expression vector pSP19T7LT and transformed into Escherichia coli strain BL21 (DE3) (which contained the plasmid pLys SL). Isopropyl beta-D-thiogalactopyranoside (IPTG; 1 mM) induced the expression of significant amounts of enzymically active protein (4 mg/l of culture as measured by Western blots). The recombinant protein was purified and characterized and found to be indistinguishable from the rat liver enzyme with regard to enzymic activity, molecular mass and N-terminal amino acid sequence. Human liver cDNA was used to obtain the coding region of human microsomal glutathione transferase by PCR. This PCR product was cloned into pSP19T7LT, which, upon induction with IPTG, yielded significant amounts (9 mg/l of culture) of active enzyme in BL21 (DE3) cells. Thus, for the first time, it is now possible to express both human and rat microsomal glutathione transferase in an enzymically active form in Escherichia coli.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Juniper, E F, et al.
(författare)
-
Asthma quality of life during 1 year of treatment with budesonide with or without formoterol
- 1999
-
Ingår i: European Respiratory Journal. - 1399-3003. ; 14:5, s. 1038-1043
-
Tidskriftsartikel (refereegranskat)abstract
- The Formoterol and Corticosteroids Establishing Therapy (FACET) study has provided the first opportunity to examine the long-term effects of inhaled steroids and long-acting beta2-agonists on asthma-specific quality of life. The objectives of the present study were to: evaluate the effects of long-term (1 yr) formoterol and increasing doses of budesonide on asthma quality of life; 2) to determine whether initial improvements in quality of life are sustained when improvements in clinical indices persist; and 3) to evaluate the long-term relationship between changes in clinical indices and changes in quality of life. Of the 852 asthmatic adults enrolled, 470 from five countries participated in this quality of life evaluation. After a 4-week run-in on 1,600 microg budesonide, patients were randomized to either 200 microg (Bud200) or 800 microg budesonide (Bud800) in combination with either 24 microg formoterol (F) or placebo daily for 1 yr. The Asthma Quality of Life Questionnaire (AQLQ) was completed and conventional clinical indices measured at enrolment and randomization and on seven occasions during the following 12 months. During the run-in, there was an improvement in AQLQ score (changes (delta) in overall score approximately 0.50; p<0.0001). After randomization, there was a further improvement in the Bud800+F group (delta=0.21; p=0.028). One month post-randomization, improvements in all groups stabilized and were sustained throughout the 12 months in a pattern very similar to that observed for the conventional clinical indices. The correlation of individual patient changes in clinical indices and changes in AQLQ score during the 12-month randomized period were weak to moderate (maximum r=0.51). Improvements in quality of life, which were greatest in the 800 microg budesonide plus 24 microg formoterol group, were sustained throughout the 12 months in a similar manner to the clinical indices. Long-term changes in conventional clinical indices cannot be used to predict the effect of treatment on individual patient experience.
|
|
